BioInvent: New BI-1808 and BI-1206 data to be presented at EHA2026 - Redeye

Today, new data from BI-1808 in cutaneous T-cell lymphoma were presented. The monotherapy efficacy (ORR of 40% in evaluable patients) is in line with previous numbers. The addition of pembrolizumab resulted in an ORR of 50%, which could position this as the preferred treatment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1166543/bioinvent-new-bi-1808-and-bi-1206-data-to-be-presented-at-eha2026?utm_source=finwire&utm_medium=RSS